ASO/siRNA RT-qPCR On/Off-Target Validation

ASO/siRNA RT-qPCR On/Off-Target Validation

1. Background

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) represent a new generation of precision nucleic acid therapeutics with tremendous potential in the treatment of rare diseases, hereditary disorders, and oncology. However, in addition to their intended therapeutic effects, these molecules may hybridize with non-target genes through sequence homology, giving rise to off-target effects that cause aberrant expression of unintended transcripts and introduce potential safety liabilities.

In recent years, major global regulatory agencies—including ICH, FDA, and PMDA—as well as the Oligonucleotide Safety Working Group (OSWG), have issued technical guidance documents explicitly requiring comprehensive sequence-dependent off-target assessments for ASO/siRNA therapeutics prior to clinical development and IND submission. Systematic off-target evaluation not only identifies potential safety risk sites but also represents a critical focus of regulatory review.

Figure 1. Overview of Key Guidance Documents from ICH / FDA / EMA / PMDA / CDE

RT-qPCR (real-time quantitative PCR), recognized as the "gold standard" in molecular biology, plays a pivotal role in the off-target evaluation framework for ASO/siRNA therapeutics. By providing targeted quantitative validation of high-risk off-target sites identified through in silico prediction and RNA-seq transcriptomic analysis, RT-qPCR enables precise assessment of the magnitude of off-target effects and delivers high-confidence experimental data to support candidate compound safety evaluation and IND submissions.

Drawing on years of experience in safety assessment services, ZhuHai GeneRulor has established a standardized RT-qPCR validation platform offering professional and reliable technical services for the confirmation of ASO/siRNA on-target knockdown efficiency and the verification of high-risk off-target sites.

2. Detection Principle and Strategy

RT-qPCR validation monitors fluorescent signal changes in real time during PCR amplification to achieve precise quantification of target gene mRNA expression levels, with a detection sensitivity reaching the single-copy level—making it the authoritative method for validating gene expression changes.

In the ASO/siRNA off-target assessment workflow, RT-qPCR validation serves two critical and complementary functions:

(1) On-Target Knockdown Efficiency Confirmation

Prior to RNA-seq experiments or in independent assays, RT-qPCR is used to precisely quantify the degree of target gene expression suppression, confirming the on-target knockdown efficacy of the ASO/siRNA and establishing a reliable positive control for subsequent off-target evaluation.

(2) High-Risk Off-Target Site Confirmation

For putative high-risk off-target sites identified through in silico prediction and RNA-seq transcriptomic analysis, RT-qPCR provides independent validation to confirm the authenticity and statistical significance of expression changes. This orthogonal validation strategy effectively eliminates false-positive signals, pinpoints true off-target sites warranting further attention, and provides clear direction for subsequent IC₅₀ determination and safety margin assessment.

Figure 2. Off-Target Assessment Technical Workflow (Complete Pipeline: In Silico Prediction → RNA-seq → RT-qPCR Validation → IC₅₀ Determination)

3. Technical Advantages

(1) High Sensitivity and Accuracy: RT-qPCR can detect gene expression changes at the single-copy level. Even for off-target genes with low basal expression, precise quantification is achievable, ensuring that no potential safety risk site is overlooked.

(2) Rapid, Efficient, and Cost-Effective: Compared to whole-transcriptome sequencing, RT-qPCR validation is highly targeted, with a shorter turnaround time (7–18 business days) and superior cost-efficiency. It is especially well-suited for rapid screening of candidate compounds and confirmation of key off-target sites.

(3) Orthogonal Validation to Enhance Data Confidence: As a validation technology independent of RNA-seq, RT-qPCR results provide orthogonal corroboration of transcriptomic data, significantly enhancing the scientific rigor and reliability of off-target assessment conclusions while meeting regulatory requirements for data integrity.

(4) Standardized Workflow Compliant with Regulatory Requirements: ZhuHai GeneRulor has established a comprehensive SOP framework encompassing primer design and validation, RNA quality control, amplification efficiency calibration, and data normalization. This ensures reproducibility and full traceability of experimental results, directly supporting IND submissions.

4. Application Scenarios

(1) On-Target Knockdown Efficiency Confirmation: During the drug design phase, rapidly validate the knockdown efficacy of candidate ASO/siRNA sequences against the target gene to provide experimental evidence for sequence optimization.

(2) High-Risk Off-Target Site Validation: Perform targeted quantitative validation of high-risk off-target genes identified by in silico prediction and RNA-seq analysis to confirm the authenticity of expression changes and identify off-target sites warranting priority attention.

(3) Dose-Dependent Assessment: Through multi-concentration gradient experiments, evaluate the relationship between expression changes of on-target and off-target genes and drug concentration, providing preliminary data for subsequent IC₅₀ determination.

(4) IND Submission Data Support: Provide RT-qPCR validation reports compliant with FDA/NMPA regulatory requirements, serving as validation data for in silico predictions and RNA-seq analyses to fulfill the completeness requirements of nonclinical safety assessments.

5. Report Contents

The RT-qPCR validation report provided by ZhuHai GeneRulor is comprehensive in content and rigorous in data quality, encompassing the following core modules:

(1) Primer Design and Validation

① Design of gene-specific primers for target genes (18–25 bp, Tm = 58–62°C)

② Standard curve-based validation of primer amplification efficiency (90–110%) and specificity

③ Melt curve analysis to confirm product singularity

(2) RNA Sample Quality Assessment

① RNA concentration and purity measurement (A260/280 and A260/230 ratios)

② RNA integrity assessment (RIN value or agarose gel electrophoresis)

(3) Quantitative Detection Results

① Ct values and normalized relative expression levels for each target gene

② Fold change in expression between experimental and control groups

Statistical significance analysis (t-test or ANOVA)

(4) Data Visualization

① Bar charts of target gene expression levels (with error bars)

② Dose-response curves (where concentration gradient experiments are performed)

(5) Quality Control Data

① Reference gene stability assessment

② Coefficient of variation (CV) across technical replicates

③ Negative and positive control results

④ All data are based on a minimum of three biological replicates to ensure statistical reliability.

6. Service Scope and Deliverables

6.1 Service Workflow

Project Consultation → Primer Design and Validation → RNA Quality Control / Sample Processing → RT-qPCR Detection → Data Analysis → Report Delivery

6.2 Deliverables

(1) RT-qPCR quantitative data tables (Excel format)

(2) Professional analytical report (PDF format), including experimental workflow, quality control data, detection results, and statistical analysis

(3) Primer sequences and validation data

(4) Raw Ct values and calculation procedures

7. Sample Submission Requirements and Project Timeline

8. References

[1] U.S. Food and Drug Administration. Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics: Guidance for Industry. Draft Guidance. November 2024.

[2] Yoshida, T. et al. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Genes Cells 24, 827–835 (2019).

[3] Andersson, P. et al. Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations. Nucleic Acid Ther. (2024).

[4] Goyenvalle, A. et al. Considerations in the preclinical assessment of the safety of antisense oligonucleotides. Nucleic Acid Ther. 2023; 33(1):1–16.